Lipocine Inc.
LPCN · XNASCIK 1535955fmd_01BJT6XS5E1H3J79R3VVCJDAZHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Sep 30, 2026, 61 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 16 | 1 | (3) | 11 | 2 |
| Research and development | 8 | 11 | 6 | 7 | 10 | 8 | 9 | 10 | 7 | 9 |
| Taxes other than income taxes | – | – | – | – | – | – | – | – | – | – |
| Total operating expenses | 19 | 21 | 12 | 13 | 18 | 13 | 13 | 15 | 12 | 12 |
| Operating income | (19) | (21) | (11) | (13) | (18) | 3 | (12) | (18) | (1) | (10) |
| Interest expense | – | – | – | 1 | 0 | 0 | 0 | – | – | – |
| Interest and investment income | – | – | – | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Other non-operating income (expense) | 0 | 0 | (0) | (0) | (3) | (4) | 1 | 2 | 1 | 1 |
| Income before taxes | (19) | (21) | (12) | (13) | (21) | (1) | (11) | (16) | 0 | (10) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (19) | (21) | (12) | (13) | (21) | (1) | (11) | (16) | 0 | (10) |
| Net income | (19) | (21) | (12) | (13) | (21) | (1) | (11) | (16) | 0 | (10) |
| Net income to common shareholders | (19) | (21) | (12) | (13) | (21) | (1) | (11) | (16) | 0 | (10) |